U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Locally Advanced Head and Neck Carcinoma

MedGen UID:
1660505
•Concept ID:
C4727839
•
Neoplastic Process

Definition

A head and neck carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes. [from NCI]

Professional guidelines

PubMed

Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types).
Nouman M, Haider G, Bukhari N, Yousuf A, Nouman R, Shaikh MR, Hussain S, Pavan B, Rahool R, Memon P, Zahoor S, Mehar K, Sami A
Asian Pac J Cancer Prev 2020 Mar 1;21(3):825-830. doi: 10.31557/APJCP.2020.21.3.825. PMID: 32212813Free PMC Article
Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.
Rambeau A, Gervais R, De Raucourt D, Babin E, Dugué AE, Florescu C, Blanchard D, Gery B
Eur Arch Otorhinolaryngol 2017 Jul;274(7):2883-2889. Epub 2017 Apr 5 doi: 10.1007/s00405-017-4550-7. PMID: 28382396
Sequential and synchronous chemo-radiotherapy in the management of locally advanced carcinoma of the head and neck.
Antognoni P, Camesasca G, Bianchi C, Nicoletti G, Villa E
Tumori 1990 Jun 30;76(3):238-43. doi: 10.1177/030089169007600306. PMID: 2368167

Recent clinical studies

Etiology

Confounding factors in the assessment of oral mucositis in head and neck cancer.
Lorini L, Perri F, Vecchio S, Belgioia L, Vinches M, Brana I, Elad S, Bossi P
Support Care Cancer 2022 Oct;30(10):8455-8463. Epub 2022 May 31 doi: 10.1007/s00520-022-07128-w. PMID: 35639187Free PMC Article
Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer.
Ameri A, Norouzi S, Sourati A, Azghandi S, Novin K, Taghizadeh-Hesary F
Cancer Rep (Hoboken) 2022 Jan;5(1):e1425. Epub 2021 Jun 7 doi: 10.1002/cnr2.1425. PMID: 34101389Free PMC Article
A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer.
Gupta P, Dhull AK, Kaushal V
J Cancer Res Ther 2020 Apr-Jun;16(3):478-484. doi: 10.4103/jcrt.JCRT_475_18. PMID: 32719254
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129.
Xiao C, Zhang Q, Nguyen-Tân PF, List M, Weber RS, Ang KK, Rosenthal D, Filion EJ, Kim H, Silverman C, Raben A, Galloway T, Fortin A, Gore E, Winquist E, Jones CU, Robinson W, Raben D, Le QT, Bruner D
Int J Radiat Oncol Biol Phys 2017 Mar 15;97(4):667-677. Epub 2016 Jul 25 doi: 10.1016/j.ijrobp.2016.07.020. PMID: 27727063Free PMC Article
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A
Lancet Oncol 2012 Feb;13(2):145-53. Epub 2012 Jan 18 doi: 10.1016/S1470-2045(11)70346-1. PMID: 22261362

Diagnosis

Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.
Rambeau A, Gervais R, De Raucourt D, Babin E, Dugué AE, Florescu C, Blanchard D, Gery B
Eur Arch Otorhinolaryngol 2017 Jul;274(7):2883-2889. Epub 2017 Apr 5 doi: 10.1007/s00405-017-4550-7. PMID: 28382396
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK
Radiother Oncol 2012 Nov;105(2):241-9. Epub 2012 Sep 23 doi: 10.1016/j.radonc.2012.08.010. PMID: 23010482
Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial.
Kankaanranta L, Seppälä T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M, Uusi-Simola J, Välimäki P, Mäkitie A, Seppänen M, Minn H, Revitzer H, Kouri M, Kotiluoto P, Seren T, Auterinen I, Savolainen S, Joensuu H
Int J Radiat Oncol Biol Phys 2012 Jan 1;82(1):e67-75. Epub 2011 Feb 6 doi: 10.1016/j.ijrobp.2010.09.057. PMID: 21300462
Mandibular lesion differential diagnoses in a patient with a previous history of locally advanced head and neck carcinoma.
Le Stanc E, Vilain D, Baglin AC, Tainturier C
Clin Nucl Med 2009 Jul;34(7):435-8. doi: 10.1097/RLU.0b013e3181a7d001. PMID: 19542949
Predictive value of flow cytometric analysis in DNA contents in patients with locally advanced head and neck carcinoma.
Wong G, Stidley C, Dressler L, Castillo M, Crooks L, Bartow S
J Laryngol Otol 1996 Mar;110(3):243-8. doi: 10.1017/s0022215100133316. PMID: 8730360

Therapy

Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer.
Ameri A, Norouzi S, Sourati A, Azghandi S, Novin K, Taghizadeh-Hesary F
Cancer Rep (Hoboken) 2022 Jan;5(1):e1425. Epub 2021 Jun 7 doi: 10.1002/cnr2.1425. PMID: 34101389Free PMC Article
Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types).
Nouman M, Haider G, Bukhari N, Yousuf A, Nouman R, Shaikh MR, Hussain S, Pavan B, Rahool R, Memon P, Zahoor S, Mehar K, Sami A
Asian Pac J Cancer Prev 2020 Mar 1;21(3):825-830. doi: 10.31557/APJCP.2020.21.3.825. PMID: 32212813Free PMC Article
Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma.
Jacinto AA, Batalha Filho ES, Viana LS, De Marchi P, Capuzzo RC, Gama RR, Boldrini Junior D, Santos CR, Pinto GDJ, Dias JM, Canton HP, Carvalho R, Radicchi LA, Bentzen S, Zubizarreta E, Carvalho AL
BMC Cancer 2018 Oct 23;18(1):1026. doi: 10.1186/s12885-018-4893-5. PMID: 30352576Free PMC Article
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Konski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, Shenouda G, Matthiesen C, Le QT, Bruner D
Int J Radiat Oncol Biol Phys 2017 Mar 15;97(4):687-699. Epub 2016 Aug 12 doi: 10.1016/j.ijrobp.2016.08.003. PMID: 27727066Free PMC Article
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A
Lancet Oncol 2012 Feb;13(2):145-53. Epub 2012 Jan 18 doi: 10.1016/S1470-2045(11)70346-1. PMID: 22261362

Prognosis

ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gkika E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke M
Pharmacogenomics J 2021 Feb;21(1):37-46. Epub 2020 Jun 16 doi: 10.1038/s41397-020-0174-1. PMID: 32546699Free PMC Article
A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer.
Gupta P, Dhull AK, Kaushal V
J Cancer Res Ther 2020 Apr-Jun;16(3):478-484. doi: 10.4103/jcrt.JCRT_475_18. PMID: 32719254
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Konski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, Shenouda G, Matthiesen C, Le QT, Bruner D
Int J Radiat Oncol Biol Phys 2017 Mar 15;97(4):687-699. Epub 2016 Aug 12 doi: 10.1016/j.ijrobp.2016.08.003. PMID: 27727066Free PMC Article
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129.
Xiao C, Zhang Q, Nguyen-Tân PF, List M, Weber RS, Ang KK, Rosenthal D, Filion EJ, Kim H, Silverman C, Raben A, Galloway T, Fortin A, Gore E, Winquist E, Jones CU, Robinson W, Raben D, Le QT, Bruner D
Int J Radiat Oncol Biol Phys 2017 Mar 15;97(4):667-677. Epub 2016 Jul 25 doi: 10.1016/j.ijrobp.2016.07.020. PMID: 27727063Free PMC Article
Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity.
Acevedo-Henao CM, Valette G, Miglierini P, Lefur E, Pradier O
Cancer Radiother 2012 Oct;16(7):601-3. Epub 2012 Oct 22 doi: 10.1016/j.canrad.2012.06.005. PMID: 23089070

Clinical prediction guides

ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gkika E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke M
Pharmacogenomics J 2021 Feb;21(1):37-46. Epub 2020 Jun 16 doi: 10.1038/s41397-020-0174-1. PMID: 32546699Free PMC Article
Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types).
Nouman M, Haider G, Bukhari N, Yousuf A, Nouman R, Shaikh MR, Hussain S, Pavan B, Rahool R, Memon P, Zahoor S, Mehar K, Sami A
Asian Pac J Cancer Prev 2020 Mar 1;21(3):825-830. doi: 10.31557/APJCP.2020.21.3.825. PMID: 32212813Free PMC Article
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Konski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, Shenouda G, Matthiesen C, Le QT, Bruner D
Int J Radiat Oncol Biol Phys 2017 Mar 15;97(4):687-699. Epub 2016 Aug 12 doi: 10.1016/j.ijrobp.2016.08.003. PMID: 27727066Free PMC Article
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129.
Xiao C, Zhang Q, Nguyen-Tân PF, List M, Weber RS, Ang KK, Rosenthal D, Filion EJ, Kim H, Silverman C, Raben A, Galloway T, Fortin A, Gore E, Winquist E, Jones CU, Robinson W, Raben D, Le QT, Bruner D
Int J Radiat Oncol Biol Phys 2017 Mar 15;97(4):667-677. Epub 2016 Jul 25 doi: 10.1016/j.ijrobp.2016.07.020. PMID: 27727063Free PMC Article
Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity.
Acevedo-Henao CM, Valette G, Miglierini P, Lefur E, Pradier O
Cancer Radiother 2012 Oct;16(7):601-3. Epub 2012 Oct 22 doi: 10.1016/j.canrad.2012.06.005. PMID: 23089070

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...